Skip to content
← Back to browse
GASTRIC Publication-derived

Establishment of a Human Colon Signet-Ring Cell Carcinoma Organoid Line (YQ-173): Culture, Characterization, and Drug Screening

Source Li et al., 2019 · Fudan University Shanghai Cancer Center · 10.2139/ssrn.3360093

👤 Yaqi Li, Renjie Wang, Dan Huang, Xiaoji Ma, Shaobo Mo, Qiang Guo, Guoxiang Fu, Yuanchuang Li, Xiaoya Xu, Xiang Hu, Yi Zhou, Yun Deng, Long Zhang, Honghong Chen, Jianjun Gao, Zhen Zhang, Sanjun Cai, Guoqiang Hua, Junjie Peng ⏱ 120 days 📋 8 phases 🧫 Patient-Derived Carcinoma (Signet-ring cell carcinoma, primary colon tumor with ovarian metastases)

Abstract

This protocol describes the establishment and characterization of YQ-173, a patient-derived organoid line from a rare human colon signet-ring cell carcinoma (SRCC). The method involves tissue digestion, 3D culture in Matrigel, optimization of culture media, and subsequent 2D monolayer derivation. The organoid line is validated for morphological, histological, genetic, and functional characteristics, and applied for personalized drug screening to identify JAK2 inhibitors as potential therapeutic agents.

Cell source
Patient-Derived Carcinoma (Signet-ring cell carcinoma, primary colon tumor with ovarian metastases)
Application
Disease modeling and drug screening for rare signet-ring cell carcinoma

Protocol overview

41 steps across 8 phases

Tissue Collection and Tumor Cell Isolation Day 0–1
  1. 1 Obtain surgical sample and consent
  2. 2 Prepare tissue for histology and DNA isolation
  3. 3 Wash tissue with PBS and digestion
  4. 4 Isolate crypts and cell aggregates
Three-Dimensional Organoid Culture Optimization Day 1–10
  1. 1 Embed isolated aggregates in Matrigel
  2. 2 Overlay with culture medium
  3. 3 Test four culture media formulations
  4. 4 Test additional growth factors
  5. 5 Select optimal medium
Routine 3D Organoid Culture and Maintenance Day 10–30+
  1. 1 Maintain and observe organoid growth
  2. 2 Refresh culture medium every 2 days
  3. 3 Passage organoids at split ratios 1:5 or 1:10
  4. 4 Bank organoid line and confirm stability
Transfer to 2D Monolayer Culture Day 30–40
  1. 1 Prepare organoids for 2D transfer
  2. 2 Dissociate organoids to single cells or small aggregates
  3. 3 Seed cells in tissue culture flasks
  4. 4 Maintain 2D cultures
Morphological and Molecular Characterization Throughout culture (sampling at Days 10, 20, 30)
  1. 1 Histology (Hematoxylin & Eosin staining)
  2. 2 Immunohistochemistry (IHC) staining
  3. 3 Immunofluorescence (IF) staining
  4. 4 RNA extraction and qRT-PCR
  5. 5 Electron microscopy
  6. 6 Chromosome analysis (Karyotyping)
Genomic Characterization: RNA-seq and DNA Sequencing Days 30–60
  1. 1 RNA isolation and RNA-seq library preparation
  2. 2 RNA-seq data analysis
  3. 3 Genomic DNA extraction
  4. 4 Capture-based targeted DNA sequencing
  5. 5 Mutation and copy-number analysis
In Vitro Drug Screening and Validation Days 40–60
  1. 1 Prepare organoids for initial drug screening
  2. 2 Screen compound library
  3. 3 Measure organoid viability after drug screening
  4. 4 Identify hit compounds and select for validation
  5. 5 Dose-response validation of selected drugs
  6. 6 Determine IC₅₀ values and select lead compound
In Vivo Xenograft Model and Drug Efficacy Testing Days 60–120
  1. 1 Prepare cells and animals for xenotransplantation
  2. 2 Subcutaneous xenotransplantation
  3. 3 Monitor tumor growth (untreated phase)
  4. 4 Randomize and treat with AT9283
  5. 5 Monitor tumor growth and body weight during treatment
  6. 6 Euthanize mice and harvest tumors
  7. 7 Histological analysis of excised tumors

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Li et al., 2019. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence